TITLE

CYTOPIA PROGRAM REACHES MILESTONE AT CANCER THERAPEUTICS

PUB. DATE
July 2009
SOURCE
Worldwide Biotech;Jul2009, Vol. 21 Issue 7, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the progress regarding a study on a pre-clinical drug candidate which has been confirmed to target the Focal Adhesion Kinase (FAK), a protein linked with many cancers. The study is a collaboration between Cytopia Ltd. and Cancer Therapeutics CRC Pty. Ltd. It is noted that the study is focused on developing inhibitors of FAK which is significant to the development of tumors.
ACCESSION #
42633241

 

Related Articles

  • Cancer Therapeutics CRC and Cytopia Ltd to collaborate on kinase target. Desjardins, Lisa; Saubern, Simon // Chemistry in Australia;Jul2008, Vol. 75 Issue 6, p36 

    The article announces that Cytopia Ltd. and Cancer Therapeutics CRC Pty. Ltd. are collaborating to develop an anti-cancer drug to treat metastatic cancers. Cytopia has extended its proprietary technology to Cancer Therapeutics to study kinase enzyme target to treat metastatic cancers. Cancer...

  • LKB1 tumor suppressor protein regulates actin filament assembly through Rho and its exchange factor Dbl independently of kinase activity. Xiaojian Xu; Omelchenko, Tatiana; Hall, Alan // BMC Cell Biology;2010, Vol. 11, p77 

    Background: Germline mutations in LKB1 result in Peutz-Jeghers Syndrome characterized by intestinal hamartomas and increased incidence of epithelial cancers. LKB1 encodes a serine/threonine kinase that plays an important role in regulating energy metabolism through the AMPK/mTOR signaling...

  • Anticancer drugs: A double strike at kinases. Harrison, Charlotte // Nature Reviews Drug Discovery;Apr2010, Vol. 9 Issue 4, p270 

    The article discusses a research being done on dual kinase inhibitor. It references the article "Disruption of engiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRβ/B-RAF" that was published in the 2010 issue. It mentions that when compared...

  • Expression and prognostic significance of focal adhesion kinase in hepatocellular carcinoma. Zhou Yuan; Qi Zheng; Jia Fan; Kai-xing Ai; Jie Chen; Xin-yu Huang // Journal of Cancer Research & Clinical Oncology;Oct2010, Vol. 136 Issue 10, p1489 

    To examine the expressions of focal adhesion kinase (FAK) and its clinical significance in hepatocellular carcinoma (HCC). We determined the expression levels of FAK on both steady-state mRNA and protein levels in 50 HCC samples by quantitative real-time PCR and immunohistochemistry,...

  • Research of shRNAmir inhibitory effects towards focal adhesion kinase expression in the treatment of gastric cancer. GUO-QIANG SU; FU-XING ZHANG; HE-HUI MAO; XIAN-WEI LIU; YONG-SHENG ZHENG; SI-YU ZHANG; JING-JUN SU // Oncology Letters;2015, Vol. 9 Issue 2, p595 

    Gastric cancer is the fourth most common type of malignant tumor, with a poor prognosis. Focal adhesion kinase (FAK) mediates the crosslink of intracellular signaling networks, playing a key role in cell migration and invasion. The aim of the present study was to investigate the effects of FAK...

  • AACR 2012.  // BioWorld Today;4/4/2012, Vol. 23 Issue 65, p3 

    The article reports on positive preclinical results for CTX0294945, the first cancer drug candidate of Cancer Therapeutics CRC Pty Ltd., as an adjuvant therapy to Avastin in triple-negative breast cancer.

  • PI3K pathway inhibitors approach junction. Holmes, David // Nature Reviews Drug Discovery;Aug2011, Vol. 10 Issue 8, p563 

    The article offers information on the developmental pathway of the drug inhibitor phosphoinositide 3-kinases ( PI3Ks) for the treatment of cancer with the combination of other inhibitors such as AKT and mammalian target of rapamycin (mTOR). It mentions that the PI3K, developed in 1993, had a...

  • OTHER NEWS TO NOTE.  // BioWorld Today;6/15/2009, Vol. 20 Issue 113, p3 

    This section offers news briefs concerning the biotechnology industry. Genaera Corp. has decided to move its assets to a liquidating trust, dismissing its remaining executives and board of directors. ImmunoGen Inc. has decided to terminate internal development of its IMGN242 gastric cancer...

  • Role of Focal Adhesion Kinase in Human Cancer: A Potential Target for Drug Discovery. Han, Edward Kyu-Ho; McGonigal, Thomas // Anti-Cancer Agents in Medicinal Chemistry;2007, Vol. 7 Issue 6, p681 

    The focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that localizes to the points of cell contact with the extracellular matrix, called focal adhesions. FAK is involved in several cellular processes including invasion, motility, proliferation and apoptosis. In in vivo animal...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics